RIVAL-01 is under clinical development by Turnstone Biologics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RIVAL-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RIVAL-01 overview

TBio-6517 (RIVAL-01) is under development for the treatment of metastatic microsatellite stable colorectal cancer, metastatic, intra or extra hepatic adenocarcinoma originating from the bile duct, metastatic cutaneous melanoma, cutaneous squamous cell carcinoma of the skin, HPV associated oropharyngeal cancer and solid tumors. The vaccine candidate consisting of the vaccinia virus backbone encoding three potent immunomodulators, Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, specifically designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. It is administered through intratumor  and intravenous route. It is developed by using Vaccinia Oncolytic Viral Immunotherapy Platform. It was under development for triple negative breast cancer.

Turnstone Biologics overview

Turnstone Biologics, is a clinical stage biotech company that developing breakthrough cancer immunotherapies. The company is headquartered in Canada.

For a complete picture of RIVAL-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.